News

Embody, Inc. Announces $10.4 Million Series C Funding Round

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it closed a $10.4 million Series C funding round led by Genesis Innovation Group’s cultivate(MD) Capital Funds LP. The financing will enable Embody to expand its world-class operations, post-market clinical studies of the recently launched Tapestry RC System for rotator cuff and prepare for the commercial launch of ActivBraid™ high-strength collagen-based suture technology in 2023.

“This financing represents a notable step in the continued growth of Embody” said Jeff Conroy, Embody’s Founder and Chief Executive Officer. “We are thrilled to have the continued support of our highly seasoned investor base, further illustrating the opportunity and need of our soft tissue healing technology portfolio.”

Embody has pioneered the next generation regenerative platform with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market, including rotator cuff repair, foot & ankle, and knee.

“Embody’s collagen technologies have the potential to redefine the standard of care and approaches to the treatment of tendon and ligament injuries,” noted Genesis Innovation Group and the cultivate(MD) venture funds Executive Director, R. Sean Churchill, MD, MBA. “We are proud to partner with Embody and believe the technology and team are well positioned to be a leader in the sports medicine market space.”

 

Learn more here.

Recent News

02/01/2023

Engineered BioPharmaceuticals to Expand in Virginia

Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at

02/01/2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate

01/31/2023

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab